GLP-1 / metabolic

Exenatide

FDA-approved

Byetta, Bydureon · GLP-1 receptor agonist (exendin-4)

First-in-class GLP-1 agonist, derived from Gila monster venom.

Half-life

~2.4 hours (Byetta); weekly ER form

Route

Subcutaneous

Evidence

FDA-approved — type 2 diabetes.

What it is

A synthetic version of exendin-4, a GLP-1-like peptide from Gila monster saliva; the first GLP-1 agonist approved (2005), in short-acting and weekly forms.

How it works

GLP-1 agonism enhances glucose-dependent insulin, suppresses glucagon, slows gastric emptying and promotes satiety.

Studied for

Glycemic control in T2D; modest weight loss.

Regulatory status

FDA-approved (some formulations discontinued commercially).

Safety

GI effects, injection-site nodules (ER); avoid in severe renal impairment; pancreatitis caution.

Reconstitution calculator →

Educational information only — not medical advice, and not a recommendation to use any compound. Many peptides here are not approved for human use; legal status and evidence quality vary and are noted above. This page contains no dosing information. Consult a qualified clinician before making any health decision.